Study Comparing Safety and Drug Interaction of UIC202502 and UIC202505 in Healthy Adults

What this Trial Is About

Researchers are evaluating the safety and how the body processes two drugs, UIC202502 and UIC202505, in healthy adult volunteers. The study is designed as an open-label, multiple-dose, two-intervention group, single-sequence crossover trial. This means participants will receive different treatments in a set order to compare their effects directly. Participants will take UIC202502 alone at one tablet per day for seven days, UIC202505 alone at one tablet per day for seven days, and then both drugs together as two tablets per day for seven days. This study includes two experimental arms and compares these treatments to observe any interactions between the drugs. During the study, participants will be closely monitored for safety and how their bodies absorb and process the drugs by measuring drug levels over 24 hours, including peak concentrations. Health assessments, diagnostic procedures, and electrocardiograms will be conducted. The study is expected to run until March 2026, with healthy adults participating throughout the treatment periods and assessments.

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers